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Abstract:  Dunaliella tertiolecta (DT)  was chemically investigated  to  isolate molecules 
inhibiting cancer cell proliferation and inducing apoptosis in vitro. The potency to inhibit 
cell growth was used for the bio-guided fractionation and isolation of active compounds 
using  chromatographic  techniques.  The  DT  dichloromethane  extract  exhibited  a  strong 
anti-proliferative activity on MCF-7 and LNCaP cells, and was further fractionated and 
sub-fractionated by RP-HPLC. High resolution mass spectrometry and spectrophotometric 
analysis  unequivocally  identified  violaxanthin  as  the  most  antiproliferative  molecule 
present in DT DCM extract. Violaxanthin purified from DT induced MCF-7 dose-dependent 
growth inhibition in continuous and discontinuous treatments, at concentrations as low as 
0.1  µg· mL
−1  (0.17  µM).  Phosphatidylserine  exposure,  typical  of  early  apoptosis,  was 
observed  after  48  h  treatment  at  8  µg· mL
−1  (13.3  µM)  but  no  DNA  fragmentation, 
characteristic  of  late  apoptosis  steps,  could  be  detected  even  after  72  h  treatment  at 
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40 µg· mL
−1 (66.7 µM). Taken together, our results demonstrate the strong antiproliferative 
activity of violaxanthin on one human mammary cancer cell line, and suggest that studying 
the pharmacology of violaxanthin and pharmacomodulated derivatives on cancer cells may 
allow potent antiproliferative drugs to be obtained.  
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1. Introduction 
Despite significant progress in prevention, diagnosis, and development during the last 25 years, 
cancer  still  represents  the  second  cause  of  mortality  in  developed  countries,  after  cardiovascular 
diseases.  Discovering  new  drugs  that  are  more  active,  more  selective,  and  less  toxic,  limiting 
deleterious side effects and tumor multidrug resistance, will obviously be a challenge for the 21st 
century.  The  isolation  of potent  anticancer  molecules from the marine environment has  generated 
interest in many groups to purify original compounds, understand their biological activity, and also 
identify  the  pharmacological  targets  of  molecules  previously  known  for  their  ecological  function. 
Extensive screening of marine microalgae has led to the isolation and chemical determination of over 
15,000  compounds,  including  fatty  acids,  sterols,  phenolic  compounds,  terpenes,  enzymes, 
polysaccharides, alkaloids, toxins and pigments [1]. The pharmacology of most of these molecules 
remains to be clearly established. Bio-guided fractionation of microalgae extracts, followed by studies 
on  human  cells,  has  demonstrated  that  many  pigments,  beyond  their  ecological  function  as  light 
harvesting molecules, also act as potent bioactive compounds on cancer cells and may have great 
potential  in  the  prevention  and  treatment  of  cancers  [2].  In  particular,  carotenoids  have  received 
increasing attention because of the decreased incidence of cancers associated with their consumption in 
fruits and vegetables [3,4]. Marine microalgae contain up to 0.2% of carotenoids (w:w dry weight)  
and  may  thus  be  of  high  interest  as  functional  food  to  prevent  cancer,  or  as  a  source  of  pure  
carotenoids  [5–7].  A  large  number  of  studies  have  demonstrated  that  purified  carotenoids  
(β,β-carotene, β,α-carotene, lutein, zeaxanthin, lycopene, fucoxanthin, astaxanthin, neoxanthin) exert a 
direct  antiproliferative  activity  on  cancer  cells  grown  in  vitro  and  induce  their  apoptosis  [8–15].  
The molecular mechanisms ruling this cytotoxicity remain to be clearly established as a large variety 
of pharmacological effectors regulating cell proliferation, differentiation and apoptosis are affected 
by carotenoids.  
As  part  of  our  ongoing  activity  dedicated  to  the  research  and  pharmacomodulation  of  natural 
anticancer compounds, we screened extracts from various microalgae species, in order to purify and 
identify  antiproliferative  molecules.  We  report  here  the  bioassay-guided  isolation  of  violaxanthin  
as  the  major  antiproliferative  pigment  in  the  dichloromethane  extract  of  the  Chlorophyceae 
Dunaliella tertiolecta. Violaxanthin exerted a potent antiproliferative activity on MCF-7 breast cancer 
cells, and induced biochemical changes typical of early apoptosis.  
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2. Results and Discussion 
2.1. Antiproliferative Activity of Microalgae Extracts  
For each extract, the concentration inhibiting 50% of cell growth (Growth Inhibition 50%; GI50) 
was determined (Table 1). 
Table  1.  GI50  (μg· mL
−1)  of  Dunaliella  tertiolecta  extracts  on  four  cancer  cell  lines.  
EtOH: ethanol; DCM: dichloromethane; >> means GI50 > 100 μg·mL
−1. 
Extraction solvent 
Cell line 
MCF-7  MDA-MB-231  A549  LNCaP 
Water  >>  >>  >>  >> 
EtOH  61.5  >>  >>  >> 
DCM  56.1  >>  >>  60.9 
DCM  and  EtOH  DT  extracts  inhibited  MCF-7  growth  with  equivalent  potency  and  at  low 
concentrations (GI50 ≈ 60 μg·mL
−1). The DT DCM extract also inhibited LNCaP growth, with a GI50 
close to the value determined on MCF-7 (GI50 = 60.9 μg·mL
−1). No extract inhibited MDA-MB-231 
growth.  The  DT  DCM  extract,  active  both  on  MCF-7  and  LNCaP  cells,  was  selected  to  purify 
antiproliferative molecules by fractionation. 
2.2. RP-HPLC Analysis, Fractionation and Sub-Fractionation of the DT DCM Extract  
Figure 1 presents the DT DCM extract chromatogram obtained at 435 nm, with the definition of the 
fractions and sub-fractions tested on MCF-7.  
Figure 1. RP-HPLC chromatogram at 435 nm of Dunaliella tertiolecta (DT) DCM extract. 
Definition  of  the  four fractions  and  the  four  sub-fractions  to  be  collected  by  
semi-preparative RP-HPLC. 
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Identification of the 11 major peaks present on the chromatogram was not performed at this step as 
we hypothesized that some fractions may not be active on cancer cells. The antiproliferative activity of 
each fraction was studied on the MCF-7 cell line as it was the most sensitive to the starting DCM 
extract, and grew faster than LNCaP. Table 2 presents the antiproliferative activity of the four DT 
DCM fractions and the four F1 sub-fractions on MCF-7.  
Table 2. GI50 (μg· mL
−1) of DT DCM fractions and sub-fractions on the MCF-7 cell line.  
>> means GI50 > 100 μg·mL
−1; > means GI50 > 40 μg·mL
−1. 
DT DCM fractions  F1  F2  F3  F4 
  GI50 (μg· mL
−1)  14.3  >>  >>  >> 
DT DCM sub-fractions  F1.1  F1.2  F1.3  F1.4 
  GI50 (μg· mL
−1)  >  20.5  18.9  11.7 
  SEM GI50 (μg· mL
−1)    2.2  8.85  0.2 
Fraction  1  (F1)  was  identified  as  the  only  active  fraction  in  the  DT  DCM  extract,  with  a  
GI50 = 14.3 μg· mL
−1. Decrease of the GI50 value compared to the DCM extract confirmed that this 
fraction was concentrated in active molecules (Table 2). The GI50 of F2, F3 and F4 were superior to  
100 μg· mL
−1 (Table 2), indicating that they did not contain potent antiproliferative molecules. F1.2, F1.3 
and  F1.4  strongly  inhibited  MCF-7  growth,  with  GI50  values  of  20.5,  18.9  and  11.7  μg·mL
−1, 
respectively (Table 2). The GI50 values of these three sub-fractions were in the range of that of the  
F1 fraction, and confirmed that the three sub-fractions contained active molecules (Table 2). The GI50 
of F1.1 was greater than 40 μg·mL
−1. Figure 2 presents the GI50 (μg·mL
−1) measured on MCF-7 with the 
starting DT DCM extract, the F1 fraction and the F1.4 subfraction. 
Figure 2. GI50 (μg·mL
−1) of DT DCM extract, F1 fraction and F1.4 sub-fraction on MCF-7. 
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The GI50 decreased with purification steps, indicating that the antiproliferative activity measured in 
the initial crude extract was not due to a synergistic action between several molecules in the mixture.  Mar. Drugs 2011, 9  
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2.3. Effect of the F1.4 Sub-Fraction on MCF-7 Growth  
The  antiproliferative  activity  of  the  most  active  sub-fraction,  F1.4,  was  assessed  on  MCF-7 
continuously exposed for 72 h to increasing concentrations in the cell culture medium. F1.4 inhibited 
MCF-7 growth at a concentration as low as 0.1 μg·mL
−1 and in a dose-dependent manner from 0.1 to 
40 μg·mL
−1 (Figure 3). 
Figure 3. Growth kinetics of MCF-7 continuously treated with the DT DCM sub-fraction F1.4. 
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A concentration of 40 μg·mL
−1 was necessary to observe a cytostatic activity on MCF-7 (Figure 3). 
MCF-7 cells were also exposed for 72 h to various concentrations of F1.4 in the cell culture medium, 
before changing the medium to a fresh control cell culture medium (Figure 4). 
Figure  4.  Growth  kinetics  of  MCF-7  during  discontinuous  exposure  to  the  DT  DCM  
sub-fraction F1.4 Change to control medium was made at t0 (gray dots). 
MCF7-Violaxanthine- 10/09/10- Croissance discontinue
Time (h)
-60 -40 -20 0 20 40 60
A
b
s
o
r
b
a
n
c
e
 
(

=
5
5
0
 
n
m
)
0,0
0,5
1,0
1,5
2,0
2,5
0.0 µg.ml
-1
2.5 µg.ml
-1
12.5 µg.ml
-1
40.0 µg.ml
-1
 Mar. Drugs 2011, 9  
 
 
824 
At all tested concentrations, the growth rate increased when the culture medium containing F1.4 was 
replaced with fresh culture medium, demonstrating that F1.4 exerted a strong antiproliferative effect, 
without however killing all cells, in the range of the pharmacological concentrations studied. 
2.4. Characterization of the Antiproliferative Molecule Contained in F1.4  
Analytical RP-HPLC at 435 nm of F1.4 demonstrated that 95% of this fraction corresponded to a 
single molecule M eluting at t = 17.326 min (Figure 5). 
Figure 5. (A) RP-HPLC chromatogram of fraction F1.4 at 435 nm. F1.4 is mainly composed 
of  a  single  molecule  M  eluting  at  t  =  17.326  min;  (B)  Absorption  spectrum  of  M  at  
tr = 17.23, 17.33 and 17.50 min (peak start, peak maximum, peak end). 
 
 
Iterative  semi-preparative  RP-HPLC  allowed the collection of 0.910 mg of F1.4 from  1500  mg 
freeze-dried DT cells, indicating that M represented 0.0576% (w:w) of the freeze-dried microalgae 
content, considering the extraction yield to be 100%. The absorption spectrum of M was characteristic 
of a carotenoid pigment and presented maximal absorption peaks at 417.2, 441.5 and 471.9 nm, with a 
band III:II ratio of 96% (Figure 5). These values were compared to data from reference spectra [16] 
which suggested that M was most probably violaxanthin, as its maximal absorption wavelengths and 
band III:II ratio were very close to the values measured with standard violaxanthin in ethanol. HRMS 
analysis unambiguously confirmed that M corresponded to violaxanthin (Table 3; Figure 6C). 
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Table 3. High resolution mass spectrometry (HRMS) identification of F1.4. 
Lead compound F1.4 
Molecular formula  [M + Na]
+ (C40H56O4Na) 
Theoretical molecular weight  623.40763 
z  1 
Theoretical m/z value  623.40708 
Experimental m/z value [M + Na]  623.4068 (0 ppm) 
Figure 6. Chemical structures of (A) fucoxanthin, (B) neoxanthin and (C) violaxanthin. 
 
2.5. Violaxanthin Induces Morphological and Biochemical Changes Characteristic of Early Apoptosis 
in MCF-7 
Figure 7 shows epifluorescence microphotographs of MCF-7 cells labeled with the DNA marker 
BOBO-1 (green) and Annexin-V-Alexa 568 (red) after 48 h incubation in the presence of various 
concentrations of violaxanthin purified from DT.  
Figure 7. Violaxanthin induces apoptosis of MCF-7 cells. Cells were incubated for 48 h  
in  the  presence  of  0,  8  or  20  μg·mL
−1  of  violaxanthin  (A,  B  and  C,  respectively). 
Fluorochromes: BOBO-1 (green) and Annexin-V-Alexa 568 (red). 
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Only a small proportion of control cells (Figure 7A) were identified as apoptotic (red arrows) or 
early necrotic (bright green spots). Violaxanthin 8 and 20 μg·mL
−1 (Figures 7B and 7C, respectively) 
evoked MCF-7 apoptosis as indicated by the important increase in the number of cells binding annexin V 
without  being  labeled  by  BOBO-1.  Only  a  few  cells  were  identified  as  late  necrotic  after  the 
violaxanthin treatment (green arrows). 
2.6. Violaxanthin Does Not Evoke MCF-7 DNA Fragmentation 
Violaxanthin doses evoking phosphatidylserine translocation in MCF-7 cells did not induce DNA 
fragmentation, even after a 72 h treatment (Figure 8B).  
Figure 8. (A) Agarose gel electrophoresis of DNA extracted from MCF-7 cells incubated 
for 72 h in the absence (lane −) or presence of 3,3′-Diindolylmethane 50 µM (DIM, control 
apoptosis  inducer)  (lane  +);  (B)  Agarose  gel  electrophoresis  of  DNA  extracted  from  
MCF-7 cells treated with violaxanthin. MCF-7 cells were incubated for 72 h in the absence 
(lane −) or presence of violaxanthin 10 μg·mL
−1 (lane 1) and 40 μg·mL
−1 (lane 2). 
 
A higher dose of violaxanthin was tested, in the range of rational pharmacological doses (40 μg·mL
−1) 
(66.4 µM), but no DNA fragmentation was observed even after 72 h incubation (Figure 8). 
3. Experimental Section  
3.1. Microalgae 
Dunaliella  tertiolecta  (DT)  belongs  to  the  Chlorophyceae  class  (green  microalgae).  The  genus 
Dunaliella exhibit a small ovoid unfrustulated cell (<20 µm), covered of cellulose, xylans, mannans 
and/or  glycoproteins,  with  two  equal  flagella  inserted  at  the  apexes  of  the  cell.  Chlorophyll  a, 
chlorophyll b, β,β-carotene, neoxanthin, lutein and violaxanthin are the main pigments described in  
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DT [17]. DT was selected as it does not contain fucoxanthin, which has already been extensively 
studied for its antiproliferative activity [9–15].  
3.2. Microalgae Culture, Collection and Storage 
Microalgae were grown at IFREMER PBA, Nantes, France. DT strain CCMP364 (CCMP, USA) 
was  cultivated  in  10  L  flasks  under  continuous  illumination  at  an  average  light  intensity  of 
180 µ mol· m
−2s
−1. Growth was performed at 20 °C , in pH unregulated batch culture, in Walne (Conway) 
medium diluted in 0.22 µm sterile-filtered natural seawater. The DT cell suspension was harvested at the 
end  of  the  exponential  growth  phase,  and  cells  were  separated  from  culture  medium  by  soft 
centrifugation (4000 g, 20 min, 10 °C ). Cells were frozen at −20 °C , sent to laboratory LIENSs, La 
Rochelle and freeze-dried at −55 °C  and P < 1 hPa, on a freeze-dryer equipped with a HetoLyoPro 
3000 condenser and Heto cooling trap (Therma Electron Corporation, France). 
3.3. Successive Extractions in Dichloromethane, Ethanol and Water 
In order to extract most microalgal organic molecules, on a wide range of polarity, successive 
extractions were performed in dichloromethane (DCM), ethanol (EtOH) and ultrapure water. A 1 g 
sample of freeze-dried microalgae powder was first extracted for 2 h in 100 mL DCM (1% w/v), at 
room  temperature,  under continuous shaking and in the dark.  The mixture was filtered through a 
PVDF0.22 μm membrane, and the DCM extract was evaporated to dryness in dark vials (45 °C , 
vacuum).  The  insoluble  residue  was  collected,  dried  and  successively  extracted  in  ethanol  and 
ultrapure water, in the same conditions, except that the water extract was collected by centrifugation 
(8000  g,  10  min,  4  °C )  and  filtered  through  a  nitrocellulose  membrane.  The  EtOH  extract  was 
evaporated to dryness in dark vials (45 ° C, vacuum) and the aqueous extract was freeze-dried. 
3.4. RP-HPLC Analysis and Fractionation 
The RP-HPLC system was composed of a binary pump (Waters, W600), an autosampler (Waters, 
W717), a thermostated (20 °C ) column compartment, and a photodiode-array detector (Waters, W486). 
Analytical RP-HPLC of the DCM extract was performed on a 20 µL sample injected in a Phenomenex 
Luna C18 (2) analytical column (250 ×  4.6 mm, 10 µm), the mobile phase consisting of a ternary 
gradient of solvent A (Methanol/water (80/20)); solvent B (Acetonitrile/water (90/10)) and solvent C 
(ethyl acetate). The gradient flow program was adapted from Jeffrey and collaborators [18], as follows: 
0 min, 100% A; 3 min, 100% B; 35 min, 30% B and 70% C; 38 min, 100% C; 41 min, 100% C;  
43 min, 100% B; 45 min, 100% A. The flow rate was 1.0 mL· min
−1 and elution was monitored at  
435 nm. Fractionation of the active extract was performed in semi-preparative conditions, using a 
semi-preparative Phenomenex Luna C18 (2) column (250 ×  10 mm, 10 µm) with a flow rate fixed  
at 5 mL· min
−1.  
3.5. Cell Culture 
MCF-7 and MDA-MB-231 human mammary carcinoma cell lines, as well as A549 human lung 
adenocarcinoma  cell  line  (LGC  Standards,  France)  were  grown  as  monolayers,  at  37  °C   in  a  Mar. Drugs 2011, 9  
 
 
828 
5%  CO2–95%  air  humidified  atmosphere,  in  DMEM  (Gibco,  France)  supplemented  with  
10% heat-inactivated (56 ° C, 30 min) FCS (Dutscher, France) to which penicillin 100 U· mL
−1 and 
streptomycin 100 μg·mL
−1 were added. LNCaP human prostatic carcinoma was grown as monolayer in 
RPMI (devoid of phenol red) supplemented with 10% heat-inactivated (56 ° C, 30 min) FCS, penicillin 
100 U· mL
−1 and streptomycin 100 μg·mL
−1. 
3.6. Cell Viability Assay 
The  algal  extracts  and  related  fractions  were  evaporated  to  dryness  and  stock  solutions  were 
prepared in DMSO before being diluted in the cell culture medium. The final DMSO concentration 
was lower than 1% and tested as a negative control. Cell viability was studied using the MTT assay. 
3.7. Detection of Early and Late Steps of Apoptosis 
3.7.1. Phosphatidylserines Translocation and DNA Staining 
Ten thousand cells were grown for 24 h on epifluorescence live cell array slides (Nunc, Dutscher, 
France) and treated for 72 h with control culture medium or microalgae extracts diluted in cell culture 
medium.  Phosphatidylserines  translocation  onto  the  outer  side  of  the  plasma  membrane  of  early 
apoptotic  cells  was  detected  using  Annexin-V-Alexa  568  fluorochrome  (Roche,  France).  Since 
necrotic cells also expose phosphatidylserines because of the loss of membrane integrity, necrotic cells 
were  distinguished  from  apoptotic  cells  by  BOBO-1  labeling.  BOBO-1  is  a  DNA-binding 
fluorochrome, excluded from living and apoptotic cells. Cells were incubated for 15 min at 20 °C  with 
the labeling mix solution, and observed using a Leica epifluorescence microscope, equipped with an I3 
epifluorescence filter block (blue excitation 450–490 nm) and a numeric camera. Early necrotic cells, 
having lost their cytoplasmic membrane integrity but with a round shaped nucleus, were labeled by 
BOBO-1  only  and  appeared  as  round  green  spots.  Early  apopotic  cells,  having  exposed 
phosphatidylserines but with no cytoplasmic membrane damages, appeared as red spots. Late necrotic 
cells exhibited a red and green co-staining and a shrunk nucleus.  
3.7.2. DNA Fragmentation 
DNA  was  extracted  and  purified  from  cancer  cells  using  a  combination  of  two  kits  
(Macherey-Nagel). In a first step, 10
6 MCF-7 cells were lysed at 70 °C  for 30 min in a lysis buffer 
(112 µL buffer T1, 25 µL proteinase K and 112 µL buffer B3 from the “Genomic DNA from Tissue” 
Kit). Then, DNA was purified using 360 µL of BB buffer (“Circulating DNA from Plasma” kit), which 
allows the purification of high and low molecular weight DNA fragments. DNA samples (5 µg) from 
control cells, cells treated with violaxanthin or cell treated with a control apoptosis inducer, DIM  
(3,3′-Diindolylmetane),  were  separated  by  electrophoresis  on  a  1.5%  agarose/Tris–borate–EDTA 
(TBE) gel, stained with ethidium bromide and compared to standards ranging from 100 to 3000 bp 
(Fermentas) using a UV transilluminator. 
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3.8. High Resolution Mass Spectrometry (HRMS) 
Accurate molecular weight of the bioactive molecules contained in DT extracts was determined by 
HRMS at the “Centre Ré gional de Mesures Physiques de l’Ouest”, University of Rennes 1, France. 
The mass spectrometer was a Bruker MicrO-Tof-Q 2, equipped with an ESI source, and samples were 
dissolved in CH2Cl2:CH3OH (90:10). 
3.9. Chemicals and Standards 
All  solvents  used  in  this  study  were  HPLC  grade.  Standard  pigments  were  obtained  from 
Chromadex, France. Ultra-pure water was obtained using a Milli-Q system (Millipore, France). 
4. Conclusions 
Breast  cancer  is  a  major  cause  of  mortality  worldwide,  and  the  development  of  new  drugs  is 
necessary to reduce mortality and limit tumor resistance to chemotherapy. This study unequivocally 
demonstrates the strong antiproliferative activity of violaxanthin on MCF-7 human mammary cancer 
cells grown in vitro and suggests that violaxanthin and derivatives obtained by pharmacomodulation 
should be studied as possible new drugs to cure breast cancer. Violaxanthin was already identified as 
possibly involved in the strong antiproliferative and pro-apoptotic activity of Chlorella ellipsoidea 
extracts on HCT116 human colon cancer cells [19]. Further studies should be undertaken to define the 
pharmacological mechanisms involved in its antiproliferative activity in human cancer cells. In this 
study,  violaxanthin  only  represented  0.0576%  (w:w)  of  the  total  freeze-dried  DT  content,  with  a 
theoretical extraction yield of 100%. Thus, it seems unrealistic to consider that violaxanthin could be 
purified from DT for therapeutic applications, even if physiological studies in Dunaliella or Chlorella 
may  be  carried  out  to  increase  production  yields.  Moreover,  there  is  no  clear  evidence  that 
epoxycarotenoids, despite their abundance in dietary fruits and vegetables, are absorbed per os by 
humans [20]. Recent studies indicate that epoxycarotenoids are metabolized before being absorbed 
per os in mice [21], suggesting that consumption of marine microalgae as functional food to obtain 
epoxycarotenoids for a putative cancer prevention or treatment is most probably less beneficial. It is, 
however, interesting to note that the oral administration of high doses of fucoxanthin in mice does not 
evoke acute or chronic toxicity, except the risk of hypercholesterolemia [22]. Additional studies will 
be necessary to get a clear understanding of epoxycarotenoids pharmacology and to consider their 
possible use to inhibit cancer cells growth in vivo. 
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